Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
8th January 2021 | Advisors Llc Perceptive | 347,332 | Open or private purchase | $9.21 | $3,198,927.72 |
8th January 2021 | Advisors Llc Perceptive | 152,668 | Open or private purchase | $10.21 | $1,558,740.28 |
8th January 2021 | Advisors Llc Perceptive | 50,000 | Open or private purchase | $7.60 | $380,000.00 |
7th January 2021 | Advisors Llc Perceptive | 500,000 | Open or private purchase | $8.13 | $4,065,000.00 |
23rd November 2020 | Advisors Llc Perceptive | 500,000 | Open or private purchase | $12.85 | $6,425,000.00 |
17th November 2020 | Martha J Demski | 7,042 | Exercise of derivative | $2.35 | $16,548.70 |
17th November 2020 | Martha J Demski | 7,042 | Bona fide gift | $0.00 | |
17th November 2020 | Martha J Demski | 7,042 | Bona fide gift | $0.00 | |
27th October 2020 | Advisors Llc Perceptive | 3,000,000 | Open or private purchase | $10.00 | $30,000,000.00 |
21st October 2020 | Advisors Llc Perceptive | 43,195 | Open or private purchase | $10.09 | $435,837.55 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center and Corporate.
5th January 2021
16th December 2020